← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV28행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
Metformin (Metformin)
AstraZeneca·Metastatic Breast Cancer
131 trials·t½ 12.4 h
Overview
Program
Metformin
Overview
Company
AstraZeneca
Overview
Modality
ANTIBODY
Overview
Target
Metastatic Breast Cancer
Overview
Indication
Metastatic Breast Cancer
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway
MoA
Biomarker
Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers
PK/PD
Half-life
12.4 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
biodistribution
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
A near-infrared fluorescent probe for imaging sulfite-associated changes in experimental renal injury.. Dissolved S(IV), present mainly as sulfite/bisulfite under near-physiological conditions, participates in sulfur metabolism and redox homeostasis, but its association with renal injury remains difficult to visualize. Here, we describe HD-ZHR, a hemicyanine-based near-infrared turn-on probe in wh…
Toxicology
CRS
Reported
Clinical
Safety signal
A near-infrared fluorescent probe for imaging sulfite-associated changes in experimental renal injury.. Dissolved S(IV), present mainly as sulfite/bisulfite under near-physiological conditions, participates in sulfur metabolism and redox homeostasis, but its association with renal injury remains difficult to visualize. Here, we describe HD-ZHR, a hemicyanine-based near-infrared turn-on probe in wh…
Clinical
Selected reported efficacy
ORR 16%
Clinical
Reported ORR
16%
Clinical
Result source
ClinicalTrials.gov NCT03800602
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT03800602